- Regeneron's ( NASDAQ: REGN ) oral IPR hearing on the IPR on ‘338 MOU patent on Wednesday suggests that the company could lose the patent, according to Jefferies.
- "We went into trial believing that REGN could lose the IPR on ‘338 MOU patent – the oral hearing yesterday reaffirms our views that Eylea could face biosimilar competition in 2024 (IPR decision ~Nov. 2022)," Jefferies analyst Akash Tewari wrote in a note.
- REGN may lose the IPR on '338 patent on grounds of both anticipation and obviousness, according to Tewari, who has an underperform rating and $536 price target on Regeneron ( REGN ). Commentary from trial judges during the hearing seems to be leaning towards Mylan, now called Viatris ( NASDAQ: VTRS ), particularly on teachings from Dixon around Eylea sequence.
- Recall in November The U.S. Patent and Trademark Office's Patent Trial and Review Board said it will review two patents related to Regeneron ( REGN ) Eylea amid a challenge from Viatris ( VTRS ).
For further details see:
Regeneron IPR hearing suggests Eylea patent may be in trouble - analyst